Key result
Oral administration of Paraliobacillus zengyii significantly decreased EV71 viral loads in mice and reduced viral RNA levels in vitro by enhancing the type I interferon response.
Why the study?
Probiotics against enterovirus 71 are mainly traditional lactic acid-producing bacteria, and most have only been proven effective in vitro.
The marine bacterium P. zengyii demonstrates promising antiviral activity against EV71 in vitro and in vivo by regulating the interferon response.
P. zengyii shows preclinical antiviral activity against EV71; hypothesis-generating in animal models, human trials needed before any clinical consideration.
Enterovirus 71 (EV71) is the major causative agent of hand, foot, and mouth disease (HFMD), leading to a serious health threat to young children. Probiotics are effective at treating or preventing gastrointestinal infections, especially viral infections. Probiotics against EV71 are mainly traditional lactic acid-producing bacteria, and most of them have been proven to be effective only in vitro. Here, we report that the marine bacterium Paraliobacillus zengyii X-1125 (P. zengyii) has promising anti-EV71 activity. The antiviral effect of P. zengyii against EV71 was assessed in different cell lines, and the viral RNA levels and titers were obviously reduced after treatment with P. zengyii. Furthermore, we established an EV71-infected mouse model to evaluate its antiviral efficacy in vivo. The oral administration of P. zengyii significantly decreased the viral loads in the hindlimb muscles, spleens, and ileums. Further research revealed that P. zengyii enhances the expression of type I interferon (IFN-I) in EV71-infected cells. Similarly, transcriptome analysis indicated that the expression of interferon-stimulated genes (ISGs) in EV71-infected mice significantly increased after P. zengyii treatment. Taken together, the results of this study indicated that P. zengyii markedly reduces EV71 infection by regulating the IFN response both in vivo and in vitro, providing a potential means to work against EV71 infection.
No takes yet. Share an insight, caveat, or question.
Fan et al. (2025) studied Enterovirus 71 (EV71) infection. Paraliobacillus zengyii X-1125 was evaluated on Viral RNA levels, titers, and viral loads. Oral administration of Paraliobacillus zengyii significantly decreased EV71 viral loads in mice and reduced viral RNA levels in vitro by enhancing the type I interferon response.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: